Overall market sentiment has been down on Coherus Biosciences Inc (CHRS) stock lately. CHRS receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Coherus Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CHRS!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With CHRS Stock Today?
Coherus Biosciences Inc (CHRS) stock has risen 2.17% while the S&P 500 is down -0.25% as of 3:41 PM on Tuesday, Nov 29. CHRS is up $0.14 from the previous closing price of $6.44 on volume of 233,917 shares. Over the past year the S&P 500 has fallen -15.06% while CHRS is down -63.85%. CHRS lost -$3.60 per share in the over the last 12 months.
More About Coherus Biosciences Inc
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Click Here to get the full Stock Report for Coherus Biosciences Inc stock.